Objective-Cholesteryl ester transfer protein (CETP) is a target gene for the liver X receptor (LXR). The aim of this study was to further explore this regulation in the monocyte-macrophage lineage and its modulation by lipid loading and inflammation, which are key steps in the process of atherogenesis. Methods and Results-Exposure of bone marrow-derived macrophages from human CETP transgenic mice to the T0901317 LXR agonist increased CETP, PLTP, and ABCA1 mRNA levels. T0901317 also markedly increased CETP mRNA levels and CETP production in human differentiated macrophages, whereas it had no effect on CETP expression in human peripheral blood monocytes. In inflammatory mouse and human macrophages, LXR-mediated CETP gene upregulation was inhibited, even though ABCA1, ABCG1, and SREBP1c inductions were maintained. The inhibition of CETP gene response to LXR agonists in inflammatory cells was independent of lipid loading (ie, oxidized LDL increased CETP production in noninflammatory macrophages with a synergistic effect of synthetic LXR agonists). Conclusion-LXR-mediated induction of human CETP expression is switched on during monocyte-to-macrophage differentiation, is magnified by lipid loading, and is selectively lost in inflammatory macrophages, which suggests that inflammatory cells may not increase the circulating CETP pool on LXR agonist treatment.
M acrophages play a central role in the formation of atherosclerotic lesions. These cells produce the cholesteryl ester transfer protein (CETP), which accounts for the enrichment of circulating apoB-containing lipoproteins with cholesteryl esters, but can also contribute to reverse cholesterol transport. 1 As shown by bone marrow transplantation experiments in mice, macrophages, including liver macrophages (Kuppfer cells), contribute significantly to plasma CETP and PLTP pools. [2] [3] [4] [5] CETP mRNA was identified mainly in nonparenchymal sinusoidal cells of the liver in cynomolgus monkeys. 6 In humans, cholesterol transfer activity was observed in the culture supernatant of human macrophages, 7, 8 and CETP was localized in macrophagederived foam cells by immunohistochemistry or in situ hybridization analysis of atherosclerotic lesions. 9, 10 CETP produced in the vicinity of the vascular bed may prevent cholesterol accumulation in lesion macrophages, 9, 11 an event involved in both early and late stages of the disease. 12 However, under unfavorable conditions (eg, when apoB-containing lipoprotein clearance is defective), the deleterious effect of systemic CETP could overcome this local beneficial effect. Accordingly, hyperlipid-emic LDLr-KO mice transplanted with CETP transgenic (CETPTg) bone marrow cells display a proatherogenic plasma lipoprotein profile and accelerated development of atherosclerotic lesions. 2 The CETP gene promoter can be transactivated in vitro and in vivo by liver X receptors (LXR). 13, 14 These oxysterol-activated nuclear receptors interact with a DR4 element in the promoter of target genes, such as CETP and ABCA1. 15 LXR are abundantly expressed in macrophages 16 where they are involved in the control of lipid homeostasis and inflammation. 17 The atheroprotective actions of LXR agonists have been clearly demonstrated in LDL receptor-and apolipoprotein E-deficient mice, 18 -20 and bone marrow transplantation studies demonstrated that this effect relies to a large extent on LXR activity in macrophages. 20, 21 Lipid entry and proinflammatory changes in macrophages are consecutive, but distinct processes and scavenger receptor-mediated lipid loading could be harmful only when associated with inflammation. [22] [23] [24] Interestingly, lipopolysaccharide (LPS)-mediated inflammation in CETPTg mice results in a profound decrease in hepatic CETP mRNA and plasma CETP concentration. 25 It remains unknown whether the regulation of CETP expression differs between macrophages and foam cells, and whether CETP gene is equally responsive to synthetic LXR agonists in early foam cells and in inflammatory cells that accumulate later in injured vascular wall. Here, we determined the expression pattern of CETP during monocyte-to-macrophage differentiation and its modulation by LXR agonists and inflammatory stimuli.
Materials and Methods
A complete Materials and Methods section is available in the supplemental materials (available online at http://atvb.ahajournals.org). Human peripheral blood monocytes were obtained from healthy donors, and macrophage differentiation was induced by M-CSF. C57Bl6 mice expressed the human CETP under the control of its natural flanking regions, and peritoneal macrophages were harvested after thioglycollate injection. Mouse bone marrow-derived macrophages were obtained by incubation of bone marrow cells with M-CSF.
Results

Upregulation of CETP Expression by an LXR Agonist in CETPTg Mouse Macrophages Derived From Bone Marrow Cells
Bone marrow cells were recovered from transgenic mice in which the human CETP gene has been placed under the control of its natural flanking regions, including the LXR␣-responsive DR4 element. 15 The differentiation of bone-marrow monocytes into macrophages was triggered by exposure to M-CSF and confirmed by expected changes in the cell morphology (supplemental Figure IA ), flow cytometry expression of F4/80 (a specific marker of mouse macrophage lineage; supplemental Figure IB ), and mRNA expression of the mouse colony stimulating factor 1-receptor (CSF1-R; supplemental Figure IC ). As shown in Figure 1A , treatment of differentiated macrophages for 24 hours with 1 mol/L of the T0901317 LXR agonist produced a significant increase in the mRNA level of LXR target genes including CETP, PLTP, and ABCA1.
CETP Gene Upregulation by LXR Agonist Is Inhibited in Inflammatory Macrophages From CETPTg Mice
CETPTg mouse macrophages that had been activated in situ by the intraperitoneal injection of thioglycollate were treated with the T0901317 LXR agonist. The LXR agonist enhanced the levels of PLTP and ABCA1 mRNA but did not induce any change in CETP mRNA levels ( Figure 1B ). LXRinduced upregulation of ABCA1 and PLTP was also observed in bone marrow-derived macrophages treated with TNF␣ or LPS (20 ng/mL and 1 g/mL, respectively; Figure  1C ). Under proinflammatory conditions, the expression level of MCP1 was magnified whereas the LXR-mediated induction of the CETP gene was abolished ( Figure 1C ). Treatment of CETPTg mice with one single dose of the T0901317 LXR agonist produced significant increases in both CETP mRNA levels in liver and cholesteryl ester transfer activity in plasma ( Figure 1D and 1E ). Most importantly, intraperitoneal injection of LPS in CETPTg mice produced no change in basal levels of liver CETP mRNA and plasma CETP activity but completely abolished the LXR-mediated upregulation of CETP ( Figure 1D and 1E).
LXR Agonist Differentially Affects CETP Gene Expression in Human Monocytes and Macrophages
Human peripheral blood monocytes (Mo) were obtained from healthy donors, and their differentiation into macrophages (Mac) was triggered by exposure to M-CSF. Spherical nonadherent monocytes acquired a typical fibroblast-like structure after 6 days of culture ( Figure 2A ). Their differentiation into macrophages was confirmed by the increased expression of CD71, the specific activation of caspase-8 as measured by using FAM-LETD.fmk as a substrate ( Figure  2B ) and the induction of the scavenger receptor A-I (SRA-I) gene ( Figure 2C ). As previously described, 26 the differentiation of monocytes into macrophages induced an increase in the expression of LXR␣ ( Figure 2D ). The expression of LXR target genes such as CETP and PLTP was also increased during the differentiation process. Exposure of peripheral blood monocytes to the LXR agonist T0901317 for 24 hours increased the expression of ABCA1 and LXR␣ mRNA without significantly affecting the level of CETP and PLTP mRNAs. In contrast, treatment of macrophages strikingly increased the mRNA levels of the four studied LXR target genes ( Figure 2D ).
LXR Agonist Induced CETP Protein Synthesis and Secretion in Human Macrophages
Western blot and lipid transfer activity analyses coincidently revealed that neither human CETP nor human PLTP could be detected in the supernatant of peripheral blood monocytes, whether the cells were treated or not with the LXR agonist ( Figure 3 ). In contrast, both PLTP and CETP were identified in the supernatant of differentiated human macrophages and their protein mass and activity levels markedly increased on exposure to the LXR agonist ( Figure 3 ).
Lipid Loading Upregulates CETP Gene Expression in Human Macrophages
Oxidized LDL induced the accumulation of cholesterol into differentiated human macrophages as judged by lipid engulf- ment and significant increase in oil red O staining ( Figure 4A and 4B). Lipid loading significantly increased the expression of CETP without affecting that of PLTP ( Figure 4C ). The synthetic LXR agonist induced a significant increase in the expression of both CETP and PLTP genes, whether the cells were pretreated or not with oxidized LDL. Both lipid loading and the LXR agonist produced a synergistic up to 90-fold rise in CETP mRNA levels in macrophages ( Figure 4C ).
Inflammation Produced Differential Effects on CETP and Other LXR Targets in Human Macrophages
Differentiated human macrophages were pretreated for 6 hours with inflammatory stimuli (TNF␣, LPS or INF␥), then treated for 24 hours with 1 mol/L of the T0901317 LXR agonist. All the inflammatory stimuli increased the level of IL1␤ mRNA ( Figure 5A) , and a concentration-dependent effect was demonstrated for TNF ( Figure 5B ). The LXRmediated induction of the ABCA1 gene was maintained in inflammatory cells, whereas the major 120-fold increase in CETP mRNA levels observed after the LXR agonist treatment was suppressed in inflammatory cells treated with TNF␣, LPS, or IFN␥ ( Figure 5A and 5B) . The moderate 4-fold increase in PLTP mRNA level was also prevented by LPS and IFN␥, with no effect of the TNF treatment. Interestingly, LXR␣ expression in macrophages was significantly induced by the LXR agonist, and this autoregulatory effect was magnified in inflammatory cells ( Figure 5C ). The T0901317 LXR agonist did no longer increase CETP mRNA and CETP activity levels in LPS-treated macrophages ( Figure  6 ). In the meantime, the ability of LXR to upregulate the ABCG1 and SREBP1c target genes was maintained ( Figure  6A ). As previously described, 27 TLR4 gene expression was upregulated after long-term (48 hours), but not after shortterm (16 hours) treatment of human macrophages with the LXR agonist (results not shown). Interestingly, and in contrast to the pretreatment with proinflammatory agents ( Figure  5A ; Figure 6A ), the LPS stimulus did no longer modify the LXR-mediated overexpression of CETP when applied after the LXR agonist treatment, with concordant observations after short-term (16-hour) and long-term (48-hour) treatments with the LXR agonist ( Figure 6C ).
Discussion
The present study shows that CETP is upregulated by LXR in differentiated human macrophages but not in human peripheral blood monocytes. The ability of LXR agonists to upregulate the CETP gene remained intact when macrophages were loaded with oxidized lipids. In contrast, it was lost on exposure to TNF␣ or LPS inflammatory stimuli. While LPS reduced the expression of the LXR target ABCA1 in J774 mouse macrophages 28 and in RAW cells, 29 the present study now indicates that LXR agonists rescue the expression of ABCA1 in primary macrophages exposed to inflammatory stimuli.
In a first attempt to bring insight into the molecular mechanism implicated in the failure of the LXR agonist to upregulate CETP expression in inflammatory macrophages, we sought for putative alteration in LXR␣ expression. This point was urged by earlier studies which demonstrated that LXR␣ expression is suppressed during the LPS-induced acute-phase response in the HK-2 human proximal tubular cell line, in human kidney mesangial cells, and in the mouse kidney. 30, 31 In contrast to these observations, it is shown here in macrophages that expression level of LXR␣ is not only maintained, but even enhanced in inflammatory cells. These observations come in new support of the existence of an LXR␣ autoregulation loop that has been described earlier. 32 However, although this mechanism may contribute to the enhanced response of the prototypical ABCA1 target gene that was observed under inflammatory conditions, it cannot apply to downregulation of the CETP gene expression. Then, we turned to explore the NFkappaB pathway because it is known to be activated in an inflammatory context and to interfere with LXR-mediated effects. 29, 33 However, involvement of this pathway in the inhibition of CETP response to LXR agonists could be excluded as inhibitors such as TPCK or PDTC, which restore ABCA1 in LPS-treated RAW cells, 29 did not restore the ability of the LXR agonist to up-regulate CETP expression in inflammatory macrophages (not shown). Finally, the molecular mechanism involved might relate to changes in the expression/recruitment of transcription factors and coactivator proteins which might have contributed to alteration of CETP expression under inflammatory conditions. Although the latter point will deserve full examination in a specific and comprehensive study, it can be anticipated that the effect of inflammatory stimuli might not simply relate to the selective displacement of LXR coactivators on the CETP promoter only. Indeed, in the present study, the LXR-mediated upregulation of CETP gene expression was disrupted by an inflammatory pretreatment, but not an inflammatory posttreatment (ie, when the LPS stimulus was applied after a former incubation with the LXR agonist). Again, results of the present study illustrate the complexity of macrophage LXR signaling and its modulation by inflammation. 27 The relative contribution of tissues and cell types to the systemic pool of CETP has long been a matter of debate. Earlier studies reported that nonparenchymal sinusoidal cells were the principal source of CETP mRNA in cynomolgus monkey liver. 6 More recently, it was shown in LDLr-KO mice transplanted with bone marrow from CETP transgenic (CETPTg) mice that liver Kupffer cells (hepatic macrophages) contributed to 50% of the total hepatic CETP expression. 2 The present study demonstrates that the capacity to produce CETP and to upregulate this production in response to LXR agonists is turned on when monocytes differentiate into macrophages. The differentiation status was already shown to affect CETP expression in other cell types (ie, CETP expression decreases during the loss of differentiation of freshly isolated human hepatocytes 34 ) as well as during the preadipocyte-to-adipocyte differentiation. 35 Over-all, observations of the present study come in further support of macrophages and Kupffer cells as significant contributors to the circulating pool of CETP, and in addition they suggest that the loss of LXR-mediated regulation of CETP expression in inflammatory cells can be of physiological relevance. Our results demonstrate that the differentiation status is only one of the parameters that determine the capability of a cell to produce CETP as inflammatory stimuli could specifically abrogate LXR-mediated secretion of CETP by macrophages. It was consistently observed in peritoneal mouse macrophages activated in situ by thioglycollate and in mouse and human macrophages obtained by ex vivo differentiation of precursors through M-CSF stimulation and exposed to TNF␣ or LPS. In support of the pathophysiological relevance of these observations, the ability of one single dose of the T0901317 LXR agonist to increase plasma cholesteryl ester transfer activity in CETPTg mice was suppressed when animals were intraperitoneally injected with LPS before receiving the LXR agonist.
As far as atherosclerosis is concerned, it should be emphasized that macrophages are heterogeneous cells with distinct inflammatory potentials and athero/inflammatory gene patterns. 36 -38 Oxidized LDL selectively increased the CETP gene expression in macrophages, suggesting that the basal expression of CETP in the vascular wall macrophages could be actually increased in initial steps of foam cell formation. In addition, exposure of lipid-loaded macrophages to the T0901317 synthetic LXR agonist strikingly increased CETP and PLTP gene expression in these cells. Conversely, the CETP gene response to LXR agonists may be selectively lost in macrophages that infiltrate advanced/inflammatory atherosclerotic lesions. To our knowledge, the antiatherogenic effect of LXR agonists has been addressed in mice that do not express CETP. Thus, the present observations will deserve further attention in animal models with either systemic or macrophage-targeted expression of CETP. Because macrophage-derived CETP was found to worsen the atherogenicity of the lipoprotein profile in the CETPTg mouse model, 2 the loss of CETP regulation by LXR agonists in inflammatory macrophages might not be detrimental. Concerns have been raised as LXR agonists increase the synthesis and secretion of triglycerides by the liver 39, 40 and enhance the cholesteryl ester uptake from HDL to macrophages. 41 In addition, LXR agonists were also suspected to increase CETP secretion into the blood stream, which may enhance the atherogenicity when the clearance of apoB-containing lipoproteins is impaired. 42 Our study indicates that, in the inflammatory conditions that characterize the atherosclerotic lesion, 12,43 LXR agonists may not promote any increase in macrophage secretion of CETP. Although the accumulation of inflammatory macrophage subpopulations should mostly be considered an indicator of a high risk of developing atherosclerosis, the present study suggests that they would actually respond in an appropriate way to LXR agonists (ie, with a rise in the expression of reverse cholesterol transport-promoting genes (ABCA1) but a reduction in the expression of potentially proatherogenic genes [CETP]). Finally, the LXR-mediated regulation of human CETP expres-sion makes it possible to distinguish between activated and nonactivated macrophage subpopulations.
It is concluded that CETP behaves as a peculiar LXR target that displays differential responses to agonists in inflammatory versus noninflammatory macrophages. Restriction of the manipulation of the LXR pathway to vascular cells has been proposed as a promising way to treat atherosclerosis. 14 The present study indicates that activated/inflammatory macrophages in the atherosclerotic plaque are specifically prevented from contributing to the circulating CETP pool on LXR agonist treatment. 
